Author: Customer Service

 Saint Herblain (France), January 09, 2026 – Valneva SE (Nasdaq: VALN; Euronext Paris: VLA), a specialty vaccine company, today announced that members of its management team will meet one-on-one with existing shareholders and hold meetings with other institutional specialist investors during the 44th Annual J.P. Morgan Healthcare Conference, January 12-14, 2026, in San Francisco. Valneva’s CEO Thomas Lingelbach and CFO Peter Bühler will discuss upcoming catalysts from its clinical development pipeline, including the pivotal data readout for its Lyme disease vaccine in the first half of this year, as well as the Company’s commercial portfolio of vaccines. To schedule a 1on1 investor meeting with Valneva, institutional investors and analysts can contact Valneva’s investor relations department at investors@valneva.com. About Valneva SE We...

In 2025 Q4, 3.6 million tonnes of cargo and 1.9 million passengers passed through the harbours of Tallinna Sadam. Compared to the same period of the previous year, cargo volumes increased by +6% i.e. 191 thousand tonnes, mainly supported by liquid bulk and ro-ro, and the number of passengers increased by +0.9% i.e. 17 thousand passengers due to the increase in the number of cruise passengers. The number of vessel calls decreased by -4.8%. The number of vehicles travelling between the Estonian mainland and the main islands increased by +7% and number of passengers by +4.5%. The number of charter days of the icebreaker Botnica declined -3.9% comparing to the same period last year. In 2025, close to 14 million tons of cargo and more than 8 million passengers passed through the harbors of Tallinna Sadam. The annual cargo volume increased by...

OSLO, Norway (9 January 2026) – TGS ASA (“TGS”), a leading global provider of energy data and intelligence, routinely publishes a quarterly operational update six working days after quarter-end. The table below shows TGS’ normalized Ocean Bottom Node (OBN) crew count¹:    Q4 2025 Q4 2024Normalized crew count Contract1 0.7 3.5Normalized crew count Multi-client1 1.0 0.01) The table shows the average number of crews in operation when assuming a normalized crew size.   The table below shows TGS’ allocation of active seismic streamer 3D vessel capacity2. In Q4 2025 Ramform Victory was used as a source vessel in West Africa and is still included in the vessel statistics.    Q4 2025 Q4 2024Contract 31% 35%Multi-client 48% 31%Steaming 15% 6%Yard 5% 6%Stacked/Standby 1% 22%Number of vessels 6 62) The statistics...

VANCOUVER, British Columbia, Jan. 08, 2026 (GLOBE NEWSWIRE) — NOVAGOLD RESOURCES INC. (“NOVAGOLD” or the “Company”) (NYSE American, TSX: NG) announces that Donlin Gold LLC (“Donlin Gold”), which is owned 60% by NOVAGOLD and 40% by Paulson Advisers LLC (“Paulson”), and Glenfarne Alaska LNG, LLC (“Glenfarne”), majority owner and developer of the Alaska LNG Project (“Alaska LNG”), signed a non-binding Letter of Intent (LOI) for natural gas supply from the Alaska LNG Pipeline and the development of the infrastructure needed to deliver the gas and power the proposed mine. Under the LOI, Glenfarne and Donlin Gold will continue to evaluate ways to formalize a potential natural gas sales agreement for up to 50 million cubic feet of natural gas per day and cooperate on the most effective method for development and construction of the Donlin...

BOSTON, Jan. 08, 2026 (GLOBE NEWSWIRE) — Monte Rosa Therapeutics, Inc. (“Monte Rosa”) (Nasdaq: GLUE), a clinical-stage biotechnology company developing novel molecular glue degrader (MGD)-based medicines, today announced the pricing of an underwritten public offering of 11,125,000 shares of its common stock at a public offering price of $24.00 per share and, in lieu of common stock to certain investors, pre-funded warrants to purchase 1,375,000 shares of common stock at a public offering price of $23.9999 per pre-funded warrant, which represents the per share public offering price of each share of common stock less the $0.0001 per share exercise price for each pre-funded warrant. Monte Rosa also granted the underwriters a 30-day option to purchase up to an additional 1,875,000 shares of common stock at the public offering price,...

Miami, FL, Jan. 08, 2026 (GLOBE NEWSWIRE) — Soren Acquisition Corp. (the “Company”) announced today the closing of its initial public offering of 25,300,000 units, which includes 3,300,000 units issued pursuant to the full exercise by the underwriters of their over-allotment option. The offering was priced at $10.00 per unit, resulting in gross proceeds of $253,000,000. The Company’s units began trading on January 7, 2026 on the Nasdaq Global Market (“Nasdaq”) under the ticker symbol “SORNU.” Each unit consists of one Class A ordinary share of the Company and one-third of one redeemable warrant, with each whole warrant entitling the holder thereof to purchase one Class A ordinary share of the Company at an exercise price of $11.50 per share. No fractional warrants will be issued upon separation of the units and only whole warrants...

SAN JOSE, Calif., Jan. 08, 2026 (GLOBE NEWSWIRE) — California Water Service Group (Group) (NYSE: CWT), the majority equity investor in BVRT Utility Holding Company LLC (BVRT) through its subsidiary, TWSC, Inc. (Texas Water), has entered into an agreement to purchase the remaining membership interests of BVRT and become the sole owner of its seven subsidiary water and wastewater utilities in the Austin-San Antonio corridor. At the same time, BVRT has continued to expand its Texas footprint through opportunities to build and enhance water and wastewater infrastructure in the area. Group expects to file a change of control application with the Public Utilities Commission of Texas (PUCT) soon to acquire the remaining BVRT membership interests. Texas Water’s acquisition of the remaining membership interests is subject to satisfaction...

Strong Balance Sheet Reflects Revenue Growth and New $125M Five-Year Facility NEW YORK, Jan. 08, 2026 (GLOBE NEWSWIRE) — Mesoblast Limited (Nasdaq:MESO; ASX:MSB), global leader in allogeneic cellular medicines for inflammatory diseases, today announced gross revenue of US$35.1 million on Ryoncil® (remestemcel-L-rknd) sales for the quarter ended December 31, 2025.1 This represents a 60% increase on the prior quarter ended September 30, 2025. Ryoncil® is the first mesenchymal stromal cell (MSC) product approved by the U.S. Food and Drug Administration (FDA) for any indication. Ryoncil® is the only FDA-approved product approved for children under age 12 with steroid-refractory acute graft-versus-host disease (SR-aGvHD),2 and will now be evaluated in a pivotal trial as part of a second-line regimen for adults with SR-aGvHD, a market...

Taipei, Taiwan, Jan. 08, 2026 (GLOBE NEWSWIRE) — Semilux International Ltd. (the “Company”) received a letter (the “MVLS Deficiency Notice”) from the listing qualifications department staff (the “Staff”) of The Nasdaq Stock Market (“Nasdaq”) notifying the Company that that from November 13, 2025 to December 30, 2025, the Company’s Market Value of Listed Securities (“MVLS”) was below the minimum of $35 million required for continued listing on The Nasdaq Global Market pursuant to Nasdaq Listing Rule 5450(b)(2)(A) (the “MVLS Requirement”). The MVLS Deficiency Notice has no immediate effect on the listing of the Company’s ordinary shares, and the Company’s common stock continues to trade on the Nasdaq Global Market under the symbol “SELX.” In accordance with Nasdaq Listing Rule 5810(c)(3)(C), the Company has 180 calendar days from...